title: Life-threatening motor neurotoxicity in association with bortezomib.
abstract: Bortezomib has been licensed to be used in relapsed and refractory multiple myeloma. It is a promising agent for this incurable condition but our effort is to caution hematologists about the life-threatening neurotoxicity (grade 4) which was seen in two of six patients treated with this agent although the complication cannot definitely be attributed to bortezomib.
authors.forename: Sunil
authors.initials: S
authors.lastname: Gupta
authors.forename: Antonio
authors.initials: A
authors.lastname: Pagliuca
authors.forename: Steve
authors.initials: S
authors.lastname: Devereux
authors.forename: Ghulam J
authors.initials: GJ
authors.lastname: Mufti
authors.forename: Steve
authors.initials: S
authors.lastname: Schey
mesh_terms: D000368:Aged; D001897:Boronic Acids / Q000009:adverse effects*; D000069286:Bortezomib; D016638:Critical Illness; D005260:Female; D006801:Humans; D008875:Middle Aged; D009101:Multiple Myeloma / Q000150:complications / Q000188:drug therapy; D020258:Neurotoxicity Syndromes / Q000209:etiology*; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced; D011719:Pyrazines / Q000009:adverse effects*
chemical_list: D001897:Boronic Acids; D011719:Pyrazines; D000069286:Bortezomib